Hint mode is switched on Switch off

CAMP4 Therapeutics, ordinary share
CAMP, US13463J1016

Add a stock to WL
Choose all Reset all
CAMP4 Therapeutics, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling ...
CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start to disease treatment, significantly reducing the time and risk to bring new medicines to patients.
Show more Hide
  • Issuer
  • Full borrower / issuer name
    CAMP4 Therapeutics Corporation
  • Industry
    Medical Services

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    CAMP
  • Placement
    11.10.2024
  • Lock up period
    180
  • Number of papers
    6,820,000
  • Volume of raised funds
    75.02 mln USD
  • Final placement price
    11 USD
  • Price change since placement date
    -62.55%
  • By capitalization
    214.56 mln USD
Other placements of the issuer
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    CAMP
  • Placement
    18.12.2025
  • Lock up period
    180
  • Number of papers
    5,000,000
  • Volume of raised funds
    30 mln USD
  • Placement share
    9.64%
  • Final placement price
    6 USD
  • Price change since placement date
    -31.33%
  • By capitalization
    311.28 mln USD

IFRS/US GAAP reports

2025
I q eng
IV q eng
2024
III q eng
IV q eng
Show all Hide

Related Stock indices

Indicators

News

18/03/2026 CAMP4 Therapeutics: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers
05/03/2026 CAMP4 Therapeutics: Results Of Operations And Financial Condition, Regulation Fd Disclosure, Financial Statements And Exhibits
22/12/2025 CAMP4 Therapeutics: Entry Into A Material Definitive Agreement, Termination Of A Material Definitive Agreement
18/12/2025 CAMP4 Therapeutics: Entry Into A Material Definitive Agreement, Financial Statements And Exhibits
17/12/2025 CAMP4 Therapeutics: Entry Into A Material Definitive Agreement, Regulation Fd Disclosure, Financial Statements And Exhibits
All organization news

Holders

Industry Leaders

Registration is required to get access.